Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib PK in Hepatic Impairment
NCT03521037Phase 1Completed
- Sponsor
- pharma&
- Start
- Feb 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of rucaparib in solid tumor (advanced stage) (2 arms), sponsored by pharma&. Primary endpoints: Maximum plasma rucaparib concentration and Area under the plasma rucaparib concentration-time curve from time zero up to the last time point with quantifiable concentration. Started Feb 2018; status: completed.
02
Drugs
rucaparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03521037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03521037.